Latest moves, page 5
- CSGP Down 14% New
CoStar falls 14% after a profit beat as net new bookings slump
CoStar beat profit forecasts and raised its outlook, but net new bookings fell by more than half and it agreed to pay about $730 million for Vexcel.
- GMAB Up 28.3% New
Genmab jumps 28% as its head and neck cancer drug halves the risk of death
Genmab's petosemtamab plus Keytruda cut the risk of death by half versus Keytruda alone in a Phase 3 head and neck cancer trial, at a first interim look.
-
GE Vernova Q3 2026: guidance up again and a $9 billion deal, with Wind still the drag
GE Vernova raised its 2026 guidance again, agreed a $9B deal for Trench Group and doubled its buyback limit. Wind and Electrification orders are the watch points.
-
Meta lines up $97.5 billion of stock sales, before options, to fund its AI build-out
After years of buybacks, Meta is selling new shares and preferred stock to help fund AI data centers. What each piece is, how it dilutes, and what to watch.
- UNF Down 10.4% New
UniFirst falls 10% on a report the FTC will sue to block the Cintas deal
UniFirst fell after Semafor reported the FTC plans to sue to block Cintas's $5.5 billion takeover, widening the gap between its share price and the offer.
- PNR Up 12.8% New
Pentair jumps 13% on a profit beat as water rival Xylem sinks 14%
Pentair rose after beating profit forecasts and saying pool dealers had finished cutting stock; water peer Xylem fell after a sales miss and a lower outlook.
- INOD Down 25.3% New
Innodata falls 25% amid reports of layoffs linked to a client ramp-down
Reports of Innodata layoffs tied to a smaller client project draw attention to its reliance on two customers that supplied 71% of Q2 revenue.
- ORIC Down 32% UPDATED OCT 31New
ORIC falls 32% after J&J shows early data for a rival prostate cancer drug
ORIC fell about 32% after J&J reported early prostate cancer results that Leerink described as a greater competitive threat to rinzimetostat.
-
Anthropic sets its IPO price at $83, topping the $70–78 range
Anthropic priced its IPO at $83, above its $70–78 range, in a 980 million-share offering worth $81.3 billion; its shares began trading on Nasdaq as ANT on Nov 19.
-
Brazil's Ibovespa sinks 14% as Lula's surprise win reverses election bets
Investors had bet on a Flávio Bolsonaro win and tighter budgets. Lula's runoff victory sent Brazil's stocks, currency and bonds tumbling.
-
Rocket Lab falls 64% since May in a space-stock rout and a Neutron delay
Rocket Lab has lost about two-thirds of its value since May as space stocks slumped, it sold about $3 billion of new stock and Neutron slipped to 2027.
- XNCR Up 15.9% UPDATED OCT 31New
Xencor jumps 16% as its kidney cancer drug shrinks tumors in early trial
Xencor reported tumor shrinkage in nearly half (5 of 11) of heavily treated kidney cancer patients at its chosen dose; the early results need confirmation.
-
IG Group falls 50% since June after its Underdog deal and a forecast cut
IG Group's shares have halved since June after a $1.3 billion US prediction-market deal paused its buyback and weaker trading revenue led to a forecast cut.
-
Sea Limited falls 44% since August on spending worries and an AI cloud bet
Sea Limited has lost 44% since August as analysts flagged Shopee's spending and competition, and an Oct 20 memo unveiled an AI cloud plan with no budget.
-
The trillion-dollar AI IPOs: what the valuations would have to prove
Anthropic priced its IPO at $83 a share, about $1.1 trillion for its shares by our count, after talk of $1.2–2 trillion. What those values assume about future profits.
-
Instacart agrees to a $17 billion sale to DoorDash at $65 a share
DoorDash agreed on Oct 29 to buy Instacart for $65 a share, about $17 billion, mostly in cash. The deal needs shareholder and antitrust approval.
-
GeneDx rose 135-fold on genome tests, then lost 66% on pay fears
GeneDx rose from $1.24 in 2023 to $167 by betting on rare-disease DNA tests, then lost about two-thirds as payments per test fell short.
- BE Down 11.2% New
Bloom Energy sinks 11% as record sales come with a cash burn
Bloom Energy beat forecasts and raised guidance, but its record quarter used $181 million of cash after a huge run, and the stock fell about 11%.
- CORT Down 20.1% New
Corcept falls 20% as a rival ovarian cancer drug aces its Phase 3 trial
Corcept had no news of its own. Genmab's Rina-S beat chemotherapy in the same ovarian cancer market as Corcept's new growth drug, Lifyorli.
- TNGX Down 16.4% UPDATED OCT 27New
Tango Therapeutics falls 16% after pancreatic cancer trial update
Tango's combination shrank tumors in 82% of 22 pancreatic cancer patients, but the stock fell 16% on a day its filing also disclosed job cuts and delays.